Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23269433 | 0.84 | EPHX2 (0.49) | EPHX2LMNAALDH1A1TSHRPLA2G2A | |
| SCHEMBL12332686 | 0.84 | EPHX2 (0.49) | EPHX2LMNAALDH1A1TSHRPLA2G2A | |
| SCHEMBL16285212 | 0.82 | PAOX (0.46) | EPHX2PLA2G2A | |
| SCHEMBL12332685 | 0.82 | TSHR (0.50) | EPHX2LMNAALDH1A1TSHRRECQL | |
| SCHEMBL24895965 | 0.81 | EPHX2 (0.47) | EPHX2LMNAALDH1A1TSHRPLA2G2A | |
| SCHEMBL6581647 | 0.80 | TET2 (0.53) | EPHX2LMNAALDH1A1TSHRPLA2G2A | |
| SCHEMBL29004439 | 0.80 | TSHR (0.52) | EPHX2LMNAALDH1A1TSHRPLA2G2A | |
| SCHEMBL16401715 | 0.80 | PRMT1 (0.59) | EPHX2LMNATSHRPLA2G2A | |
| SCHEMBL29004442 | 0.80 | TSHR (0.52) | EPHX2LMNAALDH1A1TSHRPLA2G2A | |
| SCHEMBL20210381 | 0.79 | NAMPT (0.43) | EPHX2ALDH1A1PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109312-A1 | NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | IGENICA BIOTHERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-11229711-B2 | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use | Magenta Therapeutics, Inc. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20160367699-A1 | NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SENSEI BIOTHERAPEUTICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-20160367699-A1 | NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SENSEI BIOTHERAPEUTICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-20160367699-A1 | NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SENSEI BIOTHERAPEUTICS, INC. | 2016-12-22 | — | — | US | disclosed |
| WO-2014197854-A1 | NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | IGENICA BIOTHERAPEUTICS, INC. (US) | 2014-12-11 | — | — | WO | disclosed |
| WO-2014197854-A1 | NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | IGENICA BIOTHERAPEUTICS, INC. (US) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109312-A1 | NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SDCBP, DCLRE1A, BCR | EPHX2 578/4885LMNA 1207/4885ALDH1A1 2431/4885 |
| US-11229711-B2 | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use | CLSPN, SDCBP, DCLRE1A | EPHX2 751/4885LMNA 832/4885ALDH1A1 2503/4885 |
| US-20160367699-A1 | NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SDCBP, DCLRE1A, BCR | EPHX2 578/4885LMNA 1207/4885ALDH1A1 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.